The Evaluation of Vancomycin Microspheres on Intracellular Staphylococcus aureus and the Effect of Bacteria on Eukaryotic Cell Wall Permeability

Henry Nettey1,2, Grace Lovia Allotey-Babington2, Martin J. D'Souza1

1Department of Pharmaceutical Sciences, Mercer University, Atlanta, USA; 2Department of Pharmaceutics and Microbiology, School of Pharmacy, University of Ghana, Legon, Ghana.

Received April 17th, 2013; revised May 25th, 2013; accepted June 10th, 2013

ABSTRACT

Sepsis is a host’s response to an intravascular infection; however, in most patients the disease recurs after a seemingly effective treatment. The reappearance of bacteria in the systemic circulation has been attributed to their ability to enter and hide within host endothelial cells. This study shows that internalized S. aureus is released into circulation by a possible mechanism of exocytosis through actin polymerization. Bacterial cell wall components (permeation enhancers) were significantly more effective in altering endothelial cell monolayer integrity than controls. Vancomycin has been determined to be effective in the treatment of S. aureus infections; however, the microencapsulated formulation of vancomycin was significantly more effective in reducing plasma and intra-tissue S. aureus than the conventional solution formulation. Microencapsulation of vancomycin, using albumin as a matrix, did not alter the bioactivity of the drug.

Keywords: Microencapsulation; Endothelial Cells; Permeation Enhancers; Albumin

1. Introduction

Death due to sepsis and peritonitis continues to be a problem in the intensive care unit. Despite aggressive approaches by modern day medicine, the mortality rate from sepsis is still very high. The pathogenesis of peritonitis and sepsis has been attributed mainly to the presence of microorganisms and the release of endotoxin into systemic circulation [1]. These invading microorganisms and their products tend to trigger extensive host defense mechanisms which include the release of cytokines and the activation of neutrophils and macrophages [2]. It has been shown that circulating microorganisms take refuge within professional as well as non-professional phagocytic cells [3,4]. These intracellular bacteria multiply and eventually find their way out of the cells and re-infect other cells. The mechanism by which intracellular bacteria exit host cells is still unclear, however, it has been hypothesized that the presence of bacteria and the cellular components in systemic circulation compromises the integrity of the endothelium [5]. This eventually leads to vascular leakage, multiple organ failure and death. It is the goal of this research to show that intra-endothelial S. aureus are released by exocytosis and that actin polymerization is a possible mechanism by which this occurs.

Vancomycin, a tricyclic antibiotic, has been a key player in the antimicrobial war and is often used as the antibiotic of last resort in treating most resistant S. aureus infections. Vancomycin is highly water soluble and therefore lends itself to highly efficient encapsulation by albumin. Vancomycin has been combined with microspheres of tumor necrosis factor-α (TNF-α) to effectively protect rats from S. aureus induced peritonitis [6]. Biodegradable polymers have been widely used as matrices for encapsulation of drugs. Albumin is a natural polymer that is biocompatible, biodegradable, and relatively non-toxic. It is water soluble and has effectively been used to encapsulate water soluble drugs [7-9]. Previous in vitro studies in our lab have shown that encapsulated vancomycin is more effective than the drug solution in killing intracellular S. aureus [10]. It has been shown that albumin microspheres are effectively phagocytosed by human macrophages [11]. The encapsulation of vancomycin would hopefully confer a sustained as well as targeted delivery of the drug, hence improving
the therapeutic efficacy of the drug.

The goal in the treatment of peritonitis and sepsis should be an early eradication of the causative agent and a prolonged presence of the drug (within the therapeutic range) to prevent recurrence of the disease. In this study, the uptake and exocytosis of *S. aureus* by endothelial cells was evaluated. Also the effect of bacterial cell wall components on endothelial integrity was evaluated. Finally, the effect of encapsulated vancomycin in a peritonitis rat model was assessed.

### 2. Materials and Methods

Human microvascular endothelial cells (HMEC’s) and culture media (MCDB131, supplemented EBM media) were obtained from the Centers for Disease Control (CDC). Lyophilized powder of *S. aureus* strain ATCC6538 was purchased from ATCC, Bethesda, Maryland. Tripti-case soy agar, tripitcase soy broth, culture flasks, petri dishes, transwell inserts (Costar #4750), 24-well tissue culture plates, and pipettes were purchased from Fisher Scientific Company, Norcross, Georgia. Antibiotics and other drug powders were purchased from Sigma Chemical Company (St. Louis, MO). Male Sprague Dawley rats were purchased from Harlan (Indianapolis, IN).

#### 2.1. Preparation of Microspheres

In a previous study, vancomycin loaded albumin microspheres were prepared by the spray-dry method. Drug loading in the microspheres was approximately 18.6% with an encapsulation efficiency of 89% [12]. The mean microsphere size was 5 ± 1.6 µm. The microspheres were used in all the experiments described below.

#### 2.2. Exocytosis of Intracellular *S. aureus* from HMEC’s

HMEC’s were grown to confluency in 24-well plates and exposed to *S. aureus* in the ratio of 100:1/*S. aureus*: HMEC’s. After 1 hour of exposure, cells were washed twice with sterile phosphate buffered saline (PBS) and adhered extracellular bacteria were killed using gentamicin solution (100 µg/ml) for 1 hour. In a preliminary study, the infected cells were incubated at 37°C and at various time intervals serial dilutions of the extracellular media were plated to determine the number of exocytosed bacteria, if any [10]. Results obtained from this study were used to determine the incubation time of infected cells prior to treatment with cytochalasin D. Cytochalasin D, a potent inhibitor of actin polymerization, was used to determine whether actin polymerization was involved in the release of bacteria from cells and hence in exocytosis.

After the gentamicin wash, HMEC’s were incubated in fresh media for three hours after which they were divided into two groups. One group was treated with 1 µg/ml of cytochalasin D (in MCDB131, supplemented EBM media) for two hours while the other group had no cytochalasin D treatment. The cells were washed twice with PBS and incubated in HMEC media (EBM) until ready for analysis. At various time intervals, serial dilutions of the media were plated on agar and bacterial cell count determined. HMEC’s were washed twice with PBS, and adhered extracellular bacteria were killed using gentamicin solution. The cells were then lysed for 1 hour with 1% triton-X 100 solution. Serial dilutions of cell lysates were also plated on agar to determine the intracellular bacterial count at each time point.

#### 2.3. Effect of *S. aureus* and Its Cell Wall Products on HMEC Permeability

For this group of experiments HMEC’s were grown to confluency on transwell inserts (Costar #4750). The inserts were pre-treated with 20 µl collagen, and allowed to dry in a sterile hood for two hours. 2 × 10^5 cells/insert (0.15 ml) were plated for 72 hours, which was the time required for the cells to reach confluence. 600 µl of media was added to each of the bottom wells. At the end of the incubation period, the media was removed from both the inserts and the bottom wells, cells were washed with PBS, and sterile Hanks Balanced Salt Solution (1% HBSS) was added to both the inserts and the wells. The cells which had to be challenged with *S. aureus* were exposed to the bacteria for one hour (to allow uptake) after which they were washed off with HBSS. For each plate, the cells were divided into five groups, and each group was treated with 100 µl of one of the following cell wall components or bacteria: Control (1% HBSS); Lipoteichoic acid (LTA) 100 µg/ml; Peptidoglycan (PepG) 100 µg/ml; LTA + Pep G (100 µg/ml); and *S. aureus* (SA). The permeation of Fluorescein Isothiocynate (FITC), FITC-Dextran, FITC-Human serum albumin (FITC-HSA), and SA through the HMEC monolayer was evaluated. Fluorescein compounds of different molecular weights were used to determine the extent by which the endothelial cell monolayer is compromised. Cells in each plate were exposed to one type of fluorescent molecule or bacteria. At various time points, fluorescent intensity in the bottom wells was determined with a Cytofluorometer with the emission and excitation wavelengths set to 485 and 530 nm respectively. For the permeation of *S. aureus*, serial dilutions of the bottom wells were plated at various time intervals. The wells were washed and fresh media added. The cumulative permeation of bacteria was determined at each time point.
2.4. Efficacy of Vancomycin Microspheres and Solution in Rats

The efficacy of vancomycin microspheres as compared to solution was determined in septic shock rat models. Three scenarios were evaluated: Prophylactic treatment, simultaneous treatment, and delayed treatment. In each study, the rats were divided into three groups: 1) Control group: In which rats (n = 2, one rat died before samples could be taken) were injected with blank albumin microspheres; 2) Vancomycin solution group: In which rats (n = 3) were treated with vancomycin solution; 3) Vancomycin microsphere group: In which rats (n = 3) were treated with encapsulated vancomycin.

2.5. Prophylactic Vancomycin Treatment

In the prophylactic treatment study, rats were injected intraperitoneally (IP), with drug solution, microspheres, or blank (15 mg/kg). Four hours after treatment, the rats were anesthetized; IP, with ketamine (100 mg/kg) and xylazine (10 mg/kg) and tail vein blood samples (400 µl) were obtained. The rats were then injected, IP, with 0.5 ml of a suspension of S. aureus (1.0 × 10⁸ cfu/ml). Tail vein blood samples were obtained at 4, 24, 48, 72, and 96 hrs post infection. All the rats received their respective treatments twice a day for three days. Serial dilutions of blood samples were plated on agar, and bacteremia count was obtained 24 hours after incubation at 37°C. The rats were euthanized on day five and the liver, spleen, and lungs were excised. Each organ was immediately placed in a 1% Hanks Balanced Salt solution (HBSS) with 100 µg/ml of gentamicin for 30 minutes.

The organs were washed twice with HBSS, weighed, and homogenized in 10 ml of 1% Triton-X 100 solution using a hand-held homogenizer. The homogenate was kept at 4°C for 1 hour, after which 50 µl of serial dilutions were plated on trypticase soy agar (TSA). Bacterial count per organ was determined after 24 hours of incubation at 37°C.

2.6. Simultaneous Vancomycin Treatment

In the simultaneous treatment study, the rats were weighed and anesthetized intraperitoneally (IP) with Ketamine (100 mg/kg) and xylazine (10 mg/kg) after which tail vein blood samples (400 µl) were obtained. The rats were injected, IP, with 0.5 ml of S. aureus (1.0 × 10⁸ cfu/ml). Immediately after bacterial injection, the rats were given subcutaneous (around the neck area) injections of drug treatment or control blank microspheres. Treatment was continued, IP, twice daily for three days thereafter. Blood samples were obtained at 4, 24, 48, 72, 96 hr post infection, serially diluted, and plated overnight at 37°C. On day five, the rats were euthanized, their organs removed and homogenates plated on agar.

2.7. Delayed Vancomycin Treatment

In a real case scenario, a patient is normally infected by a microorganism before treatment is initiated. The delayed treatment of infected rats mimics a real case situation. In this study, the rats were injected, IP, with 0.5 ml of S. aureus (1.0 × 10⁸ cfu/ml). Four hours after infection, the rats were anesthetized, and tail vein blood samples were obtained. These were serially diluted and plated on agar. The rats were then given IP injections of drug microspheres, solution, or control. Tail vein blood samples were obtained at 8, 24, 48, 72, and 96 hr post infection, serially diluted, and plated overnight at 37°C. All the rats received their respective treatments twice a day for three days. On day five, the rats were euthanized, their organs removed and homogenates plated on agar.

2.8. Statistical Analysis

All data were analyzed using a two-tailed t-test.

3. Results and Discussions

3.1. Exocytosis of Intracellular S. aureus from HMEC’s

The number of internalized bacteria increased steadily with time, however no bacteria was exocytosed in the first 5 hours of incubation (Figure 1). There was no analysis of the extracellular media between 5 and 24 hours, however after 24 hours of incubation, exocytosed bacteria was detected in the media. The number of exocytosed bacteria increased thereafter with time. These results were used to determine the incubation time of infected HMEC’s prior to treatment with cytochalasin D. The number of intracellular S. aureus increased with time in the cytochalasin D untreated cells, whereas the number of intracellular bacteria decreased in the treated cells.

Figure 1. Internalized bacteria were eventually exocytosed from HMEC’s. Exocytosis of internalized S. aureus occurs after 5 hours of incubation. Both the number of internalized and exocytosed bacteria increased with time.
There was a significantly higher number of intracellular bacteria in the cytochalasin D untreated cells at 9 and 24 hours of incubation than in treated cells, \( p < 0.05 \). The number of exocytosed bacteria from cytochalasin D untreated cells was significantly higher than those released from cytochalasin D treated cells at 7 and 24 hours of incubation (Figure 2). These results indicate that cytochalasin D was effective in inhibiting both uptake and exocytosis of \( S. aureus \), hence actin polymerization is a possible mechanism of exocytosis. Our results confirm what others have found: That the actin cytoskeleton is involved in exocytosis [13].

### 3.2. Effect of \( S. aureus \) and Its Cell Wall Products on HMEC permeability

The effect of Lipoteichoic acid (LTA), peptidoglycan (Pep G), and \( S. aureus \) on the permeability of various molecular weight compounds through an endothelial cell monolayer was evaluated. Previous studies have shown that LTA can cause moderate hypotension in rats, but is unable to cause multiple organ failure or death by itself. [14] However, both LTA and pepG act in synergy to release TNF-\( \alpha \) and gamma-interferon (IFN-\( \gamma \)), and to cause shock and multiple organ failure in anesthetized rats [15]. The first compound analyzed was FITC. PepG, PepG + LTA, and \( S. aureus \) were all significantly more effective than the control (1% HBSS) in increasing the permeation of FITC, \( p < 0.05 \) (Figure 3). The permeation of FITC-Dextran through the HMEC monolayer showed a similar result as that seen in the case of FITC. FITC-Dextran, being a higher molecular weight molecule than FITC alone, showed a rather slower rate and smaller amount of permeation through the monolayer. All the compounds used were more effective than the control (1% HBSS) in increasing the permeation of FITC-Dextran; however, there was a significantly higher permeation effect only after 1 hour of incubation, \( p < 0.05 \) (Figure 4). In the case of FITC-HSA permeation, no permeation of HSA was observed until after one hour of exposure, and this effect was observed after exposure to the combination of PepG + LTA. The combination of PepG + LTA was most effective in altering the monolayer integrity after three hours of exposure (Table 1). Table 2 shows the effect of lipoteichoic acid (LTA), Peptidoglycan (PepG), LTA + PepG, and \( S. aureus \) (SA) on the permeation of \( S. aureus \) through HMEC monolayer. Only LTA and LTA + PepG were effective in significantly increasing the permeation of \( S. aureus \) at all time points \( p < 0.05 \).

### 3.3. Prophylactic Vancomycin Treatment

Drug administration to a person prior to exposure to disease is rare, unless where vaccines are involved or where one expects to be exposed to the disease-causing pathogen. In the case of bacterial infections, treatment prior to exposure is even rarer; however, for hospital workers (in the case of nosocomial infections), pre-surgical wounds, and soldiers in the battlefield, prophylactic treatment with antibiotics might be necessary. In this study, treatment of rats prior to exposure to \( S. aureus \) showed that the presence of drug decreased the circulating bacterial load considerably. Moreover, vancomycin in the microsphere formulation was more effective in reducing the overall bacterial load than the solution form or blank microspheres. Between 4 and 24 hr after infection, there was a decrease in bacteremia in all groups. This could be due to cellular uptake of circulating bacteria. Increase...
The Evaluation of Vancomycin Microspheres on Intracellular Staphylococcus aureus and the Effect of Bacteria on Eukaryotic Cell Wall Permeability

389

-0.0005

0

0.0005

0.001

0.0015

0.002

0.0025

0.003

0.0035

Concentration (mg/ml)

Time (hrs)

Figure 4. The effect of lipoteichoic acid (LTA), Peptidoglycan (PepG), and S. aureus (SA) on the permeation of FITC-Dextran through HMEC monolayer. All the compounds used were more effective than the control (1% HBSS) in increasing the permeation of FITC-Dextran, however, there was a significantly higher permeation effect only after 1 hour of incubation, p < 0.05.

Table 1. Effect of LTA, PepG, LTA + PepG and S. aureus on FITC-HSA permeation through endothelial monolayer.

<table>
<thead>
<tr>
<th>Time (hr)</th>
<th>Control</th>
<th>LTA</th>
<th>Pep G</th>
<th>LTA + PepG</th>
<th>SA</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.00 ± 0.00</td>
<td>0.00 ± 0.00</td>
<td>0.00 ± 0.00</td>
<td>0.00 ± 0.00</td>
<td>0.00 ± 0.00</td>
</tr>
<tr>
<td>0.5</td>
<td>0.00 ± 0.00</td>
<td>0.00 ± 0.00</td>
<td>0.00 ± 0.00</td>
<td>0.00 ± 0.00</td>
<td>0.00 ± 0.00</td>
</tr>
<tr>
<td>1.0</td>
<td>0.00 ± 0.00</td>
<td>0.00 ± 0.00</td>
<td>0.00 ± 0.00</td>
<td>0.21 ± 0.30</td>
<td>0.00 ± 0.00</td>
</tr>
<tr>
<td>1.5</td>
<td>0.00 ± 0.00</td>
<td>0.00 ± 0.00</td>
<td>0.20 ± 0.10</td>
<td>2.00 ± 0.40</td>
<td>0.00 ± 0.00</td>
</tr>
<tr>
<td>2.0</td>
<td>0.00 ± 0.00</td>
<td>0.14 ± 0.40</td>
<td>2.07 ± 0.40</td>
<td>0.00 ± 0.00</td>
<td></td>
</tr>
<tr>
<td>2.5</td>
<td>0.50 ± 0.37</td>
<td>0.09 ± 0.10</td>
<td>2.20 ± 0.13</td>
<td>2.87 ± 0.61</td>
<td>0.74 ± 0.70</td>
</tr>
<tr>
<td>3.0</td>
<td>0.95 ± 0.37</td>
<td>1.50 ± 0.99</td>
<td>3.17 ± 0.51</td>
<td>3.96 ± 0.41</td>
<td>1.56 ± 1.20</td>
</tr>
</tbody>
</table>

*Statistically significant difference at p < 0.05 compared with control (media).

Table 2. Effect of LTA, PepG, LTA+PepG and S. aureus on S. aureus permeation through endothelial monolayer.

<table>
<thead>
<tr>
<th>Time (hr)</th>
<th>Control</th>
<th>LTA</th>
<th>Pep G</th>
<th>LTA + PepG</th>
<th>SA</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.00 ± 0.00</td>
<td>0.00 ± 0.00</td>
<td>0.00 ± 0.00</td>
<td>0.00 ± 0.00</td>
<td>0.00 ± 0.00</td>
</tr>
<tr>
<td>1.0</td>
<td>165 ± 35</td>
<td>225 ± 22</td>
<td>200 ± 29</td>
<td>314 ± 6</td>
<td>144 ± 51</td>
</tr>
<tr>
<td>2.0</td>
<td>199 ± 27</td>
<td>299 ± 13</td>
<td>230 ± 43</td>
<td>396 ± 16</td>
<td>197 ± 68</td>
</tr>
<tr>
<td>3.0</td>
<td>205 ± 22</td>
<td>352 ± 30</td>
<td>257 ± 49</td>
<td>454 ± 4</td>
<td>232 ± 60</td>
</tr>
</tbody>
</table>

*Statistically significant difference at p < 0.05 compared with control (media).

in bacterial load after that could be due to exocytosis of internalized bacteria (Figure 5). Tissue analysis after five days of infection also confirmed the bacteremia results: Vancomycin microspheres were significantly more effective in reducing tissue bacteria load than either solution or blank microspheres (Figure 6). In all cases the bacterial load in the whole of the liver was higher than in either the spleen or the lung, however, the number of bacteria per gram of liver was less than in either organ.

3.4. Simultaneous Vancomycin Treatment

Simultaneous treatment of S. aureus infected rats produced similar results as the prophylactic treatment, although not as significant a difference. Vancomycin microspheres reduced the bacteremia levels more than either blank microspheres or vancomycin solution (Figure 7); however a significant difference in bacterial levels was seen only at 48 and 96 hours post infection. The presence of bacteria in the systemic circulation despite treatment could be due to either low systemic drug concentration or continued exocytosis of intracellular bacteria. It is possible that bacterial multiplication exceeded drug action.

Tissue analysis after five days of infection also showed that vancomycin microspheres were more effective in reducing intracellular bacterial load than either van-
comycin solution or blank microspheres (Figure 8). In all cases the blank microsphere group had the largest number of bacteria in the tissue.

3.5. Delayed Vancomycin Treatment

In the delayed treatment of *S. aureus* infected rats it was observed that the solution form was better than the microsphere form in reducing the plasma bacterial load after 8 hours of infection. It is expected that by the time treatment is initiated, the systemic and intracellular bacterial load would be very high due to bacterial multiplication. The dose of drug used was unchanged; hence the bacteremia count was high due to insufficient drug action. A possible explanation for the higher efficacy of vancomycin solution after eight hours of infection is that, the drug was readily available in the solution form. Drug release from the microsphere formulation increased with time thereafter and that was the reason for the decreased bacterial load at later time points. Vancomycin microspheres reduced the bacteremia load significantly more than either the solution or the blank microspheres at 48 and 72 hours post infection (Figure 9).

Analysis of tissue samples excised after five days of infection showed that vancomycin microspheres were more effective than either solution or blank microspheres in reducing the bacterial load in the liver and spleen (Figure 10). There was no significant difference between the formulations in reducing the bacterial load in the lungs (p > 0.05).

4. Conclusions

It can be concluded from these results that *S. aureus* is exocytosed after it is taken up by endothelial cells. Exocytosis and phagocytosis of bacteria occur simultaneously, however, initially, the rate of phagocytosis far exceeds exocytosis. With increasing intracellular bacterial load, the exocytosis rate as well as extracellular bacterial multiplication exceeds phagocytosis. The partial inhibition of exocytosis by cytochalasin D and the decreasing intracellular bacterial load shows that actin po-
lymerization is a possible mechanism of exocytosis as well as phagocytosis. The profound effect that the combination of LTA and PepG had on the endothelial cell monolayer integrity shows that both components of the gram positive cell wall are required for vascular leakage to occur considerably.

In vivo challenge studies of peritonitis rat models supported previous in vitro results that vancomycin microspheres were more effective in killing intracellular bacteria [10]. In all three scenarios, namely prophylactic, simultaneous, and delayed treatment, the microencapsulated form of vancomycin was more effective in reducing the systemic bacterial load than either blank microspheres or free vancomycin. Similar results were seen in the tissue analysis of bacteria levels.

The comparable distribution of both microspheres and bacteria in the spleen and liver will ensure effective killing of microbes (by encapsulated drugs) which infect these organs. In cases where the lungs are the infected organs, microspheres of larger sizes (>7 µm) would be more effective. In sepsis, bacteria within endothelial cells are the main target; hence treatment would be more effective if professional phagocytes are initially saturated with blank microspheres, before treatment is initiated.

5. Acknowledgements

This study was supported by the Dialysis Clinic, Atlanta and Mercer University Southern School of Pharmacy.

REFERENCES


